Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners formulary Prior Auth & Coverage | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    Formulary prior authorization and step therapy coverage criteria (Commercial)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    HealthPartners commercial formulary guidance describing prior authorization (PA) and step therapy (ST) rules for pharmacy drugs; applies to providers and members under the commercial pharmacy benefits.

    Policy Summary
    PayerHealthPartners
    PolicyFormulary prior authorization and step therapy coverage criteria (Commercial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and provide required documentation (trial history, specialist notes, provider attestations or linked PA forms) for drugs designated as prior authorization or step therapy required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    manydrugs listed with PA/ST descriptors
    linksentries referencing external PA documents
    multiplereserved for allergic reaction to generic
    manyprior auth / reserved designation
    >=70Nexletol/Nexlizet LDL threshold

    Coverage Criteria Overview

    General formulary PA/ST criteria

    Covered when product-specific prior authorization or step therapy criteria are met as described below or in the linked external coverage pages.

    General PA/ST requirements: 1) Drug is included on the HealthPartners drug list; AND 2) The drug meets the PA criteria or step therapy requirements specified for that product (including required trial of preferred alternatives or documented contraindication/allergy); AND 3) If external product-specific criteria are cited, approval follows those referenced documents.

    Many entries list either 'reserved for patients with a documented allergic reaction to the equivalent generic' or require inadequate response to specified number of preferred alternatives; some entries direct to external PDFs for full criteria.

    General Step Therapy / Prior Authorization criteria (segment)

    Covered when meeting product-specific ST/PA criteria

    General ST/PA requirement: Patient has inadequate response to specified preferred products (commonly two) OR has medical contraindication to preferred alternatives OR has documented allergic reaction to equivalent generic, per product listing.
    Policy Summary
    PayerHealthPartners
    PolicyFormulary prior authorization and step therapy coverage criteria (Commercial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and provide required documentation (trial history, specialist notes, provider attestations or linked PA forms) for drugs designated as prior authorization or step therapy required.
    SourceLink
    On This Page
    Coverage Criteria OverviewProvider Actions and Documentation RequirementsKey Coding and ThresholdsInitial Therapy and Authorization RulesContinuation / Reauthorization RequirementsStep Therapy Rules and Product TablesQuantity and Supply LimitsSite-of-Care and Specialty PrescribingDefinitionsSelected Initial Authorization ExamplesSelected Continuation / Renewal ExamplesBackground and ScopeRevision History
    varies by product (often 1-2 failed preferred products)

    Some products require additional documentation or link to a product-specific PA form.

    General step therapy / prior authorization logic

    Coverage is generally reserved when ALL of the following types of conditions are met as specified per product:

    General product conditions: Product is used for an FDA‑approved indication or per product‑specific clinical criteria; AND the patient has had an inadequate response to required number of preferred alternatives (commonly one or two) OR has a documented allergic reaction to the equivalent generic OR has medical contraindication to preferred products; AND any product‑specific documentation (e.g., specialist prescribing, weight for dosing, trial durations) is provided.see individual product entries

    This is the repeated pattern across multiple product entries in the excerpt.

    Long-acting opioid prior authorization requirement

    Long-acting opioids listed require additional attestation:

    Long-acting opioid attestation: Provider attestation that therapy is being managed per standard opioid prescribing guidelines and that the patient had an inadequate response to a recent adequate trial (minimum 30 days continuous use) with a short-acting opioid.30 days

    Appears for buprenorphine-containing long-acting opioids and certain branded long-acting opioids.

    General PA/ST criteria (multiple listed products)

    Coverage reserved when specified product-specific conditions are met

    General product rules: Products are reserved for patients with documented allergic reaction to equivalent generic OR inadequate response to preferred alternatives (number of failed alternatives varies by product: one, two, or three) OR when FDA-approved indication requires specialist prescribing or other specific conditions.varies by product

    See individual product lines for exact required number of failed alternatives or documentation

    Cystinosis (CYSTADROPS, CYSTARAN)

    Cystinosis products

    CYSTADROPS/CYSTARAN initial and renewal: 1) Prescribed by a specialist; 2) Diagnosis of cystinosis; 3) Initial approval for 3 months; renewals require slit lamp exam documentation of clinical treatment effect and are provided for up to one year.initial 3 months; renewals up to 1 year

    Document slit lamp exam notes for renewal

    DALFAMPRIDINE ER criteria

    DALFAMPRIDINE ER (for MS-related ambulation)

    DALFAMPRIDINE ER initial and continuation: 1) Diagnosis: multiple sclerosis; 2) Patient currently able to walk 25 feet; 3) Physician attestation patient has difficulty walking; 4) Prescribed by a neurologist; 5) Dosage not exceeding FDA approved 10 mg twice daily; 6) Initial approval 6 months; continuation requires documented improvement in ambulation for yearly approvals.initial 6 months then yearly if benefit

    Documented improvement in ambulation required for renewal

    EMFLAZA coverage stance

    Deflazacort / EMFLAZA

    Brand deflazacort (EMFLAZA): Brand deflazacort will be considered not medically necessary because evidence does not establish superiority over less costly alternatives; brand reserved for patients with documented allergic reaction to equivalent generic.N/A

    Coverage restricted; considered NMN except for allergy to generic

    Covered with criteria (product-specific)

    Coverage is generally conditional; products are covered only when the listed product-specific PA/step-therapy requirements are met.

    General conditions: Patient has diagnosis appropriate for the drug AND documentation of inadequate response to required number of preferred alternatives OR documented medical contraindication or allergic reaction to preferred/generic alternatives; where specified, provider attestation or literature documentation of superiority required.varies by product

    See individual product PA link or reserved note for exact required trials or documentation.

    General reserved coverage conditions (excerpt)

    Coverage reserved or requires prior authorization under specified conditions (per drug); common patterns listed below reflect the document's repeated reservation language.

    Common reservation patterns: Coverage for individual drugs is reserved when ONE of the following applies: documented allergic reaction to equivalent generic/brand; inadequate response to one or two preferred alternatives; medical contraindication to preferred alternatives; FDA-approved indication-specific criteria met; product-specific external prior authorization documentation provided; for long-acting opioids, additional attestation and prior short-acting trial required.

    Pattern derived from multiple entries in chunks 90–109

    Gattex coverage criteria

    Gattex-specific initial and reauthorization criteria

    Gattex initial approval: Adult patients with short bowel syndrome significantly impaired in functional capacity due to chronic parenteral nutrition requirements (e.g., >= 4L daily) who have been dependent on parenteral nutrition for at least one year.parenteral nutrition >= 4L/day; dependence >=1 year

    Initial approvals granted for three months

    Gattex reauthorization: Reauthorizations provided for up to a year with a documented reduction in parenteral nutrition volume requirements.documented reduction in parenteral nutrition volume

    Doses up to 5 mg daily approved; other doses reviewed case-by-case

    Opioid prior authorization criteria

    Long-acting opioid requirements

    Long-acting opioid prior auth: Reserved for patients who have tried and failed two preferred products or have medical contraindications; provider attestation required that therapy is managed per standard opioid prescribing guidelines and reserved for patients with an inadequate response to a recent adequate trial (minimum 30 days continuous) with a short-acting opioid.>=30 days short-acting opioid trial

    Applies to specified ER opioids in this excerpt

    Coverage reservation patterns (I-L list)

    Coverage reservations and common criteria patterns in this document segment

    Reserved for FDA-approved indications: Coverage allowed only for FDA-approved indications; may require prior authorization and documentation of inadequate response to preferred alternatives in some cases.

    Examples: IMPAVIDO, JUVENILE products; approvals sometimes time-limited (e.g., 6 months for some agents).

    Reserved for inadequate response to preferred alternatives: Coverage reserved when patient has had an inadequate response or intolerance to one or two preferred alternatives.inadequate response to 1 or 2 preferred alternatives as specified per product

    Common across insulin and many other agents (e.g., multiple insulin products, LANTUS).

    Reserved for documented allergic reaction to equivalent generic: Brand product coverage limited to patients with documented allergic reaction to the equivalent generic (often requires documentation).documented allergic reaction

    Used for various agents (e.g., IMITREX formulations, INDERAL, KEPPRA).

    Special product-specific criteria via URL: Several products reference an external prior authorization criteria document (link provided) which contains the full coverage rules.follow referenced URL for full criteria

    Example links provided for IMBRUVICA, INBRIJA, INCRELEX, INFLECTRA, etc.

    Time-limited approvals and prior authorization durations: Some agents have initial approval durations specified (e.g., 6 months) and require demonstration of response for renewal.examples: 6 months initial approval

    Shown for agents like LANREOTIDE, KYGEVVI, LEROCHOL.

    General product coverage criteria (L–M)

    Covered when ALL of the following conditions (as specified per product) are met

    Preferred trial: Patient has had an inadequate response to specified number of preferred alternatives (commonly two; sometimes one or three depending on product) unless a medical contraindication exists.number of preferred alternatives varies by product

    See individual product entry for exact required number of trials.

    FDA indication: Use is consistent with FDA‑approved indications when specified.

    Many entries state 'Reserved for FDA-approved indications'.

    Allergy exception: Documented allergic reaction to the equivalent generic allows coverage of brand product when specified.

    Multiple entries list this exception.

    Opioid attestation: For long-acting opioids, provider must attest therapy is managed per standard opioid prescribing guidelines and patient had an inadequate response to an adequate trial (minimum 30 days continuous) of a short-acting opioid.30 days

    Applies to specified long-acting opioid entries.

    General coverage/reservation logic

    Covered when product-specific criteria are met (examples below reflect language used across multiple entries in this segment):

    Common product-level reservation rules: Products are reserved for: (a) patients with documented allergic reaction to the equivalent generic/biosimilar; or (b) patients with inadequate response to one or more preferred alternatives (explicitly one, two, or three depending on product); or (c) only for FDA-approved indications; or (d) prescribing by or in consultation with a specified specialist; or (e) when external product-specific PA documentation is provided.

    Language varies by product; see product entry for exact number of required prior failures or specialist requirement.

    Nexletol / Nexlizet

    Nexletol/Nexlizet: 1) FDA-approved indication; AND 2) inadequate response defined as LDL cholesterol >= 70 mg/dL despite standard therapy (high-intensity statin), or medical contraindication to statins; AND 3) inadequate response to ezetimibe or documented allergy/contraindication to ezetimibe. Approvals are given for one year; reauthorization requires documented LDL reduction per provider attestation.LDL >= 70 mg/dL

    Long-acting opioid coverage

    Long-acting opioids (examples: morphine ER, MS Contin, Nucynta ER): 1) Reserved for patients who have tried and failed two preferred products or have medical contraindications to preferred products (varies by product); AND 2) provider attestation that therapy is managed per standard opioid prescribing guidelines, including evidence of inadequate response to a recent adequate trial (minimum 30 days) of a short-acting opioid.30 days short-acting opioid trial

    Some products also allow exception if documented allergy to generic.

    Nuzyra

    Nuzyra (omadacycline): 1) FDA-approved indication; AND 2) prescribing by or in consultation with Infectious Disease providers; AND 3) inadequate response to standard treatments or medical contraindication to them. Culture and sensitivity results are required.

    Standard treatments include quinolones for CAP and linezolid for ABSSSI.

    Ocaliva advisory

    Ocaliva (note): Health care professionals are instructed to stop prescribing Ocaliva; see Primary Biliary Cholangitis (PBC) policy for more information.

    Safety advisory in this segment.

    Common PA and step therapy coverage patterns (excerpt)

    Entries specify coverage reserved conditions or link to detailed PA documents; common covered condition patterns appear below.

    Allergic reaction to generic: Coverage reserved for patients with a documented allergic reaction to the equivalent generic (example products across excerpt).documented allergic reaction

    Appears for many products (e.g., OLUX-E, ONFI, ORACEA, OXICONAZOLE, PRADAXA, PROAIR, etc.).

    Inadequate response to preferred alternatives: Coverage reserved for FDA-approved indications or other uses when patient has an inadequate response to two preferred alternatives (some items require three).failure of 2 preferred therapies (some require 3)

    Examples include OMEPRAZOLE-SODIUM BICARBONATE (three preferred therapies), OSMOLEX ER, OSPHENA, PRALUENT, etc.

    FDA-approved indication only: Some products are reserved strictly for FDA-approved indications unless otherwise specified; PA documents referenced for full criteria.FDA indication

    Examples: ORALAIR, PALFORZIA, PLEGRIDY, PREVYMIS, etc.

    Opioid long-acting criteria: Long-acting opioids require: (1) trial/failure of two preferred products or medical contraindication; and (2) provider attestation of management per opioid prescribing guidelines, including a recent adequate trial (minimum 30 days continuous) of a short-acting opioid.30 days

    Applies to OXYCODONE HCL ER, OXYCONTIN, OXYMORPHONE HCL ER.

    PEGASYS HCV/HBV specifics: For hepatitis B or C use, PEGASYS requires specialist prescribing, documentation of genotype/viral load for HCV, prior intolerance to Peg-Intron for HCV, combination with specified agents, and duration limits (HBV up to 48 weeks; HCV genotype 1 up to 48 weeks; genotypes 2 or 3 up to 24 weeks).duration limits

    Detailed in chunk 174.

    General reserved coverage criteria

    Covered with prior authorization when specific conditions are met:

    Common conditions for reserved coverage: Coverage reserved for patients with documented allergic reaction to the equivalent or preferred generic, OR inadequate response to one or two preferred alternatives, OR medical contraindication to preferred alternatives; some drugs require FDA-approved indication or specialist prescribing; documentation of clinical benefit over preferred alternatives may be required.

    Applies variably by drug as noted in individual entries

    Pulmozyme

    Pulmozyme coverage conditions:

    Pulmozyme initial approval: Reserved for cystic fibrosis patients when prescribed and managed by specialists from a cystic fibrosis treatment center; initial approvals for 12 months.12 months initial approval

    Renewals annual with documentation of CF center visit within last 12 months and medication effectiveness

    Drugs withdrawn/not eligible

    Relyvrio coverage stance: Relyvrio is not eligible for coverage through HealthPartners as of 4/4/2024 because it has been withdrawn from the market; contact manufacturer for information.

    General coverage patterns for R–S products in this segment

    Coverage determinations for listed drugs follow one of the patterns below depending on product:

    Pattern A - FDA indication required: Drug is reserved for FDA-approved indications; prior authorization requires that the prescription matches labeled uses.

    examples: RUKOBIA, RYKINDO, many entries link to external criteria

    Pattern B - Inadequate response to preferred alternatives: Drug covered when patient has an inadequate response to preferred alternatives (often two), or medical contraindication to their use; prior auth must document the trials/contraindication.trial/failure of two preferred alternatives (where specified)

    examples: ROXYBOND (some strengths), SAVAYSA, SEROQUEL XR, SPINOSAD

    Pattern C - Documented allergic reaction to equivalent generic: Drug coverage reserved for patients with a documented allergic reaction to the equivalent generic or preferred generic product; prior auth must document allergic reaction.documented allergic reaction

    examples: ROXICODONE, SEROQUEL, SEROQUEL XR, SUMADAN, many others

    Pattern D - Specialty prescriber or condition-specific requirements: Coverage requires prescribing by or consultation with a specialist per FDA label or program (e.g., Infectious Disease, Neurology) or other condition-specific rules; some agents require demonstration of response for ongoing approvals.specialist prescribing or lab/response documentation as specified

    examples: RUFINAMIDE (Neurology), SIRTURO (Infectious Disease), SIGNIFOR (response documented)

    General coverage and PA logic (T–Z)

    Coverage and prior authorization vary by product; many drugs are covered only after meeting specific conditions such as trial/failure of preferred alternatives, documented allergies to generics, or meeting detailed PA documents linked in the entry.

    Link-referenced PA criteria: For many listed products the prior authorization requirement is defined in an external PA document (URL provided). Providers must follow the linked criteria.

    See individual entries for URLs

    Step therapy: inadequate response: Coverage is reserved for patients with an inadequate response to one or more preferred products or preferred dosage forms, or with medical contraindications to preferred products.

    Several entries require documentation in the medical literature when asserting superiority; see product-specific entry

    Allergy/Generic exemption: Coverage reserved for patients with a documented allergic reaction to the equivalent generic or preferred generic product.

    Multiple entries use this exemption

    Specialty program requirements: Certain specialty medicines (e.g., inhaled tobramycin) require specialist management (e.g., CF treatment center), quantity limits, and periodic documentation of effectiveness and specialist visits.

    See tobramycin entries

    Opioid-specific edits: Immediate-release opioid new users limited in days supplied; longer or ER opioid therapy requires provider attestation of guideline-managed care and prior adequate trials.

    Applies to tramadol products and other IR/ER opioids noted

    Extracted coverage condition examples

    Coverage for listed products is variable; examples of stated coverage conditions in this extract include:

    Allergic reaction to generic: Coverage reserved for patients with a documented allergic reaction to the equivalent generic formulation (multiple products).

    Referenced throughout listings (e.g., TROKENDI XR, ULTOMIRIS, VYVANSE).

    Inadequate response to preferred alternatives: Coverage reserved for FDA‑approved indications for patients with an inadequate response to two preferred alternatives or with medical contraindications to their use; documentation of benefit over preferred alternatives may be required.trial of 2 preferred alternatives

    Referenced for many topical/injection/oral products (e.g., ULTRAVATE, VEVYE, WYNZORA).

    Specialty prescriber / diagnosis-specific requirements: Some drugs require prescribing by a specialist and diagnosis-specific criteria plus prior trial failures (e.g., VIBERZI requires gastroenterology prescribing and trials of conventional therapies).specialty prescriber, trial failures

    See VIBERZI entry in chunk 244.

    Illustrative step therapy criteria

    Examples of product-specific step requirements from the extract (each product has its own rule as noted):

    Altabax: Covered if generic mupirocin ointment was used within previous 3 months; otherwise prior authorization may be required.3 months
    Carbidopa-levodopa ER: Covered if carbidopa/levodopa ER capsule or generic carbidopa/levodopa used within previous 12 months; otherwise prior authorization may be required.12 months
    Dexcom / FreeStyle Libre: Coverage references external prior auth documents and notes member must have been using insulin in the previous 6 months.6 months (insulin use)
    Topical calcineurin inhibitors / Eucrisa/Opzelura/Vtama/Zoryve/Zoryve-like: Covered if generic tacrolimus ointment or pimecrolimus cream used within specified prior period (commonly 12 months or 365 days); otherwise PA may be requested.12 months or 365 days
    Repatha: Covered if member used a generic statin within the previous 12 months; otherwise prior authorization may be required.12 months
    Trintellix: Covered if member used a listed generic antidepressant within previous 12 months; otherwise PA may be required.12 months
    Zolpidem ER: Covered if generic zolpidem regular release used within previous 12 months; otherwise PA may be required.12 months

    Some branded products in this formulary are designated not medically necessary because the available evidence does not establish superiority to less costly alternatives. Examples called out in the list include products such as Agamree, which is specifically stated to be considered not medically necessary for that reason. When a brand is considered not medically necessary on this basis, coverage is limited to situations where an explicit exception is documented (for example, a documented allergic reaction to the equivalent generic) as described on the individual product entry or referenced PA document.

    Certain topical or over‑the‑counter products are subject to step therapy or limited coverage and will be approved only when there is documentation of an allergic reaction or inadequate response to specified OTC or generic alternatives. The policy highlights examples where coverage is reserved when the member has a documented allergic reaction to the equivalent OTC alternative (for example, prior use of benzoyl peroxide or generic mupirocin within a specified lookback period) or when required prior use of preferred topical agents is shown in the medical record or PA submission.

    This excerpt does not establish any single broad formulary exclusion category. Instead, coverage and exclusions are handled on a per‑product basis and many entries refer providers to product‑specific prior authorization pages or PDFs for the full criteria. Providers must consult the linked product coverage pages or the HealthPartners public PA documents referenced in each drug entry for the detailed exclusion or exception language applicable to that product.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for many drugs listed on the HealthPartners formulary. Providers must obtain PA for medicines designated as “prior authorization required” or “Reserved” before the drug will be covered at the plan’s standard benefit tier.

    • Apply for PA using HealthPartners prior authorization processes and forms where required.
    • Many product entries reference product-specific PA criteria or PDFs — follow the linked criteria when present.
    Prior Authorization

    Prior Authorization Required for Reserved Products

    Several products are marked “Reserved,” meaning coverage is limited to specific clinical scenarios. Prior authorization requests for reserved products typically require documentation of an inadequate response to preferred alternatives, or documentation of a medical contraindication or allergy to preferred/generic options.

    • When a product is Reserved, include prior trial history or allergy/contraindication documentation.
    • Some Reserved products require documentation from the medical literature showing clinical benefit over preferred alternatives.
    Documentation Required

    Product‑Specific Prescriber/Clinical Requirements

    Some products have product‑specific prescriber, age, specialty, or clinical requirements (e.g., AUVI‑Q dosing/weight/anaphylaxis history; DALFAMPRIDINE ER requires neurologist prescribing and physician attestation). Check each product entry or linked PA criteria for these requirements and include supporting documentation in the PA request.

    • Examples: AUVI‑Q: may have weight/age and anaphylaxis history requirements.
    • DALFAMPRIDINE ER: neurologist prescriber, baseline ambulatory status and physician attestation, initial 6‑month trial with documented ambulation improvement for continuation.
    • NUZYRA: prescribing by or consultation with Infectious Disease, culture/sensitivity results required.
    Prior Authorization

    Cayston PA Duration & Renewal

    Cayston (aztreonam inhalation) prior authorization specifics: approvals limited to cystic fibrosis patients with documented Pseudomonas aeruginosa; must be prescribed and managed by a cystic fibrosis treatment center specialist; quantity limited to one 28‑day package per month. Initial approvals are for 12 months; renewals annually require documentation the patient was seen within the last 12 months at the CF center and the medication remains effective.

    • Prescriber must be a CF treatment center specialist.
    • Quantity limit: one 28‑day package per month.
    • Initial approval: 12 months; renewals: annually with CF center visit documentation and effectiveness note.
    Prior Authorization

    Prior Authorization Required for Listed Products

    Many listed drugs are subject to prior authorization; criteria vary by product and often reference external product‑specific PA PDFs or web pages. Providers must follow the linked PA criteria when provided and submit the required clinical documentation.

    • Follow the product‑specific PA URL or PDF referenced in the formulary entry.
    • If no external link is provided, include diagnosis, prior treatments, and rationale for non‑preferred or brand use.
    Denial Risk

    EMFLAZA Prior Authorization / Not Medically Necessary (NME)

    Some drugs (examples: EMFLAZA/deflazacort, JAYTHARI, KYMBEE, PYQUVI) are designated Not Medically Necessary (NME) or will be considered NME unless specific circumstances apply (e.g., documented allergy to generic). Provide clear justification when requesting brand coverage under those limited circumstances.

    • EMFLAZA (deflazacort): considered not medically necessary; brand may be reserved for documented allergic reaction to generic.
    • Document allergy testing or medical history supporting inability to use lower‑cost alternatives.
    Documentation Required

    Duration‑Limited Approvals

    Some approvals are duration‑limited. Examples: fidaxomicin approvals limited to a 10‑day course; many specialty agents (e.g., somatostatin analogs, Gattex) have initial short‑term approvals then require response documentation for longer continuations.

    • Include requested duration and planned reassessment data in PA requests.
    • Provide objective measures of response when available (e.g., LDL reduction for Nexletol/Nexlizet, reduced parenteral nutrition for Gattex).
    Prior Authorization

    Prior Authorization Reserved for Specific Clinical Reasons

    Certain products are reserved for specified clinical reasons (e.g., allergy to generic, failure of two or more preferred agents, specific diagnostic criteria, or specialist prescribing). Ensure PA documentation clearly states the specific clinical reason aligning with the reserved indication.

    • State the exact reserved reason (allergy, failed trials, FDA‑indication requirement) used to justify coverage.
    • Attach supporting records: allergy history, chart notes of failed trials, diagnostic test results, or specialist consultation notes.
    Prior Authorization

    External Prior Authorization Forms Referenced

    When a formulary entry references an external PA form or criteria PDF, include that documentation or follow the instructions on that page for submitting PA. Those external documents contain full criteria and required documentation lists for many specialty products.

    • Examples: Forteo, Fyarro, Gazyva, Gleevec entries link to product‑specific PA PDFs.
    • If an external form is required, uploads should include completed form and supporting clinical notes.
    Prior Authorization

    Product‑Specific Prior Authorization

    Many products require product‑specific prior authorization with distinct intake requirements. Always consult the product entry or linked PA criteria and supply the exact information requested (diagnosis codes, prior therapies, lab values, culture/susceptibility results, prescriber specialty and attestation when required).

    • Provide culture/sensitivity results for antibiotics when requested (e.g., Nuzyra).
    • Include genotype/viral load for HCV products per linked criteria when applicable.
    Prior Authorization

    PA Requirement Overview

    PA Requirement Overview: PA ensures drugs meet HealthPartners coverage rules. Common PA elements include confirming FDA‑approved indication (or acceptable off‑label rationale), prior trial/failure of preferred agents (step therapy), documented allergy/contraindication to preferred/generic agents, specialist prescribing when required, and necessary clinical measurements or test results.

    • Include diagnosis, prior treatment history (dates/doses), reason for non‑preferred use, relevant labs or imaging, and specialist notes when applicable.
    • If a PA is denied for lack of required documentation, resubmission with the missing evidence may be requested.
    Prior Authorization

    PEGASYS Prior Authorization Specifics

    PEGASYS (peginterferon alfa‑2a) PA specifics: prescribing must be by a gastroenterology, hepatology, or infectious disease specialist; covered for treatment of HBV or HCV only and, for HCV, requires genotype and viral load documentation and intolerance or adverse effects to prior peg‑interferon therapy. Duration limits: HBV up to 48 weeks; HCV genotype 1 up to 48 weeks; genotypes 2 or 3 up to 24 weeks. Use must align with combination regimens meeting HealthPartners criteria.

    • Prescriber specialty required: gastroenterology, hepatology, or infectious disease.
    • HCV: include genotype and viral load, and documentation of intolerance/adverse effects to prior Peg‑Intron.
    • Specify planned regimen and duration consistent with PA criteria.
    Prior Authorization

    Prior Authorization Overview

    Overall prior authorization overview: Providers must obtain PA when indicated; PA supports appropriate, evidence‑based use, manages specialty drug utilization, and documents that less costly or safer alternatives were tried when required. Failure to obtain required PA may result in coverage denial or member financial liability.

    • Verify PA requirements on the formulary or linked product criteria before prescribing.
    • Submit comprehensive clinical documentation to reduce processing delays.
    Documentation Required

    Follow Referenced PA Criteria

    Follow the referenced PA criteria and external links for product‑level details. Many PA denials are avoidable when the provider submits the specific documents outlined in the linked criteria (completed PA form, relevant labs, specialist notes, culture results, prior trial dates).

    • If a product entry includes a URL or PDF, use that as the source of required documentation.
    • Attach any completed manufacturer or payer PA forms if requested.
    Step Therapy

    Step Therapy Denial Trigger

    Step therapy denial trigger: Coverage for medicines subject to step therapy will be denied for lower‑cost tiers unless prior authorization is obtained demonstrating the member has met step requirements (tried and failed specified preferred alternatives), or an approved exception is documented (allergy/contraindication).

    • Document dates and durations of prior trials when requesting exceptions.
    • Allergy/contraindication must be specific and supported by clinical records.
    Denial Risk

    Failure to Meet Step‑Therapy Prerequisites

    Failure to meet step‑therapy prerequisites will commonly result in denial. Providers should document trials and failures of the required preferred alternatives within the specified lookback period (often 12 months unless otherwise stated) or provide clinical justification for an exception.

    • Include medication name, dose, dates, reason for discontinuation (e.g., lack of efficacy, adverse effects).
    • If lookback period applies, show timing of prior trials relative to PA request.
    Prior Authorization

    Cayston Specialist & Quantity Requirement

    Cayston specialist and quantity requirement reminder: Cayston must be prescribed and managed by CF treatment center specialists, and quantity is limited to one 28‑day package per month. Include CF center visit notes and culture data in renewal requests.

    • Specialist prescribing required: cystic fibrosis treatment center.
    • Quantity limit: one 28‑day package/month; renewals require CF visit within prior 12 months.
    Denial Risk

    Not Medically Necessary Designation (Example)

    When a product is designated not medically necessary (example: EMFLAZA/deflazacort), include only the narrowly specified exceptions (e.g., documented allergic reaction to generic) if applicable; otherwise expect denial.

    • Provide allergy documentation or objective testing supporting inability to use the generic alternative.
    • If no exception applies, consider prescribing the covered alternative.
    Denial Risk

    Failure to Meet Documented Step‑Failure Requirements

    Failure to document required step failures (dates, durations, and clinical reasons), specialist involvement, or other product‑specific prerequisites will typically trigger denial. Include thorough chart notes and medication histories to avoid delays.

    • Chart notes should state inadequate response, intolerance, or contraindication to specified preferred agents.
    • Attach consultant notes or test results supporting the requested therapy.
    Denial Risk

    Missing Opioid Attestation / Trial Documentation

    Missing opioid attestation or trial documentation: Long‑acting opioids and certain agents (including tramadol ER) require a provider attestation that therapy is managed per standard opioid prescribing guidelines and documentation of an adequate recent trial (minimum 30 days continuous use) of a short‑acting opioid when reserving long‑acting therapy. New IR opioid users are limited in initial supply without PA.

    • Provide provider attestation detailing opioid management plan and risk mitigation.
    • Document at least 30 days of continuous short‑acting opioid trial for long‑acting opioid PA requests.
    Denial Risk

    Failure to Meet Step Therapy Trials

    Failure to meet step therapy trials will lead to denial unless a documented allergy or medical contraindication exempts the member. When step trials are required, provide dates, agents, and reasons for failure. Some products require two or more failed preferred agents.

    • Specify which preferred agents were tried and why they failed.
    • If allergy is cited, include testing or contemporaneous clinical notes.
    Documentation Required

    Documentation Requirement

    General documentation requirement: include diagnosis, prior therapies (names, doses, dates), treatment response, relevant laboratory or imaging data, culture/sensitivity results when applicable, specialist consultation notes, and completed PA forms or product‑specific checklists.

    • Attach lab values (e.g., LDL for Nexletol/Nexlizet; HCV genotype/viral load for HCV therapy).
    • Include objective response measures when continuation approvals are requested.
    Denial Risk

    Long‑Acting Opioid Attestation Required

    Long‑acting opioid attestation required: For long‑acting opioids, provide an attestation that the patient’s opioid therapy is being managed per standard opioid prescribing guidelines, including documentation of a recent adequate trial with a short‑acting opioid (minimum 30 days) and risk mitigation measures.

    • Include plan for monitoring, PDMP checks, urine drug testing as indicated, and treatment goals.
    • Specify prior short‑acting opioid trial duration and response.
    Documentation Required

    Nexletol / Nexlizet LDL Requirement

    Nexletol / Nexlizet LDL requirement: For PCSK9 adjuncts and related lipid agents (Nexletol/Nexlizet), include baseline LDL ≥ 70 mg/dL despite high‑intensity statin therapy (or documented contraindication/intolerance) and trial of ezetimibe unless contraindicated. Approvals are typically given for one year with re‑authorization requiring documented LDL reduction per provider attestation.

    • Document baseline LDL ≥ 70 mg/dL and prior statin intensity/duration.
    • For reauthorization, provide LDL change or provider attestation of clinical benefit.
    Denial Risk

    Long‑Acting Opioid Attestation and Trial

    Long‑acting opioid attestation and trial: Reiterate that long‑acting opioids require both evidence of prior short‑acting opioid adequacy and provider attestation of guideline‑based opioid management. This applies to products such as Hysingla ER, MS Contin, Nucynta ER, Tapentadol ER, Morphine ER, etc.

    • Include prior short‑acting opioid trial details and reasons it's insufficient.
    • Provide opioid management plan and monitoring measures.
    Prior Authorization

    Nuzyra Infectious Disease Requirements

    Nuzyra infectious disease requirements: Nuzyra is reserved for FDA‑approved indications and requires prescribing by or consultation with Infectious Disease providers for patients with inadequate response to standard treatments or contraindications. Culture and sensitivity results are required.

    • Attach culture and sensitivity reports and Infectious Disease consultation notes.
    • Document trials of standard therapies (e.g., quinolones for CAP, linezolid for ABSSSI) and reasons for failure.
    Denial Risk

    Opioid Provider Attestation Requirement

    Opioid provider attestation requirement: For many opioid products, the prescriber must attest that therapy is being managed per opioid stewardship guidelines, including risk assessment, monitoring, and intent to limit long‑term use when appropriate.

    • Attestation should reference use of PDMP, urine drug screening plans, and treatment goals.
    • Include specialty clinic involvement if applicable.
    Documentation Required

    FDA‑Indication / Prior Trial Documentation

    FDA‑indication / prior trial documentation: For drugs reserved for FDA‑approved indications only, provide documentation of the diagnosis that matches the FDA indication. For drugs reserved after failure of preferred products, provide the prior trial documentation and clinical rationale for use of the non‑preferred agent.

    • Attach diagnostic test reports, specialist notes, or operative reports supporting the FDA‑indication.
    • List prior therapies with dates and reasons for discontinuation.
    Denial Risk

    Denial Triggers (Summary)

    Denial triggers (summary): common denial reasons include missing PA when required, inadequate documentation of prior trials or allergies, missing specialist prescriber requirements, absent provider attestations (opioids), missing lab/test results (e.g., HCV genotype, LDL), or failure to follow external product‑specific PA forms.

    • Before submission, verify linked PA criteria and ensure all requested documents are included.
    • Incomplete submissions are likely to be denied or delayed.
    Denial Risk

    Failure to Meet Step Therapy Prerequisites

    Failure to meet step therapy prerequisites: reiteration that denials will occur when required lower‑cost alternatives have not been tried within the plan’s lookback period (commonly 12 months) or when the documentation does not demonstrate inadequate response or intolerance.

    • Provide exact dates of prior trials within the lookback window.
    • If prior therapy occurred outside the lookback window, include rationale and prior records to support exception.
    Billing Rule

    Opioid Quantity / Attestation Requirement

    Opioid quantity / attestation requirement: For immediate‑release (IR) opioids new users, initial fills are limited (example: 7‑day first fill, 14‑day episode total). Longer therapy or long‑acting opioid use requires PA with provider attestation and documentation of trials. Quantity limits and age edits for certain agents (e.g., tramadol age limits) must be observed.

    • Document justification for quantities exceeding initial limits and include attestation for chronic use.
    • Observe age edits (e.g., tramadol reserved for adults and children ≥ 12 years).
    Prior Authorization

    CF Center Prescribing and Documentation Requirement

    CF center prescribing and documentation requirement: Several CF‑related products (Cayston, TOBRAMYCIN injectables/inhalation forms, Pulmozyme, Prezcista/Prescribed and managed by CF center) require specialist prescribing and annual CF center follow‑up documentation for renewals. Include culture data and evidence of clinical benefit on renewals.

    • Initial approvals often 12 months; renewals require CF center visit within prior 12 months and documentation of effectiveness.
    • Attach sputum culture showing Pseudomonas when required.
    Denial Risk

    Denial Risk for Missing Required Trials/Specialty

    Denial risk for missing required trials/specialty: Requests lacking required trials, specialist prescribers, or essential labs/tests as specified in product criteria are at high risk for denial. Use the linked product PA criteria to confirm required elements before submission.

    • Checklist: diagnosis, prior trials (dates/reasons), specialist note if required, labs/cultures, completed PA form.
    • If any element is missing, include a plan and expected timeline for obtaining it to support a conditional approval request.
    Denial Risk

    Failure to Meet Step Lookback

    Failure to meet step lookback: For step therapy rules that require prior trials within a lookback period (commonly 12 months), inability to demonstrate those trials within the lookback will lead to denial unless clinical justification or prior records are supplied.

    • Provide prior medication fill history from the EHR or pharmacy records to demonstrate compliance with lookback requirements.
    • If prior trials predate the lookback, provide reasons and clinical rationale for exception.
    Documentation Required

    External Prior Authorization Documentation

    External PA documentation: many product entries reference external prior authorization criteria pages or PDFs. These external documents list the full clinical criteria and required evidence; consult them and include the requested documents when submitting PA.

    • Examples: numerous product entries link to healthpartners.com product‑specific PDFs.
    • If the external document requires a completed form, include it with the PA submission.
    Documentation Required

    Supporting Clinical Documentation

    Supporting clinical documentation: PA submissions should include clinical notes showing inadequate response/intolerance to preferred agents, objective measures of treatment effect, relevant labs/imaging, and specialist letters when required. For continuation requests, document therapeutic benefit.

    • For continuation: include documentation of clinical benefit (e.g., improved ambulation for DALFAMPRIDINE ER, reduced PN volume for Gattex, documented improvement for therapies with time‑limited initial approvals).
    • For novel or non‑preferred uses, include supporting literature if the product is reserved post‑failure of preferred agents.
    Documentation Required

    Cholbam Documentation and Reauthorization

    Cholbam documentation and reauthorization: For ursodiol/Cholbam and similar hepatobiliary agents, include patient weight for dosing verification, initial documentation of clinical response, and for reauthorizations provide evidence of liver function improvement and ongoing benefit.

    • Include weight for dose calculations.
    • For reauthorization, attach labs demonstrating improvement in liver tests or clinical status.
    Documentation Required

    Specialist Prescribing and Renewal Documentation

    Specialist prescribing and renewal documentation: Certain agents (CYSTADROPS, CYSTARAN, cystinosis therapies, CF products) require specialist prescribing and limited initial approvals (e.g., three months); renewals require clinical treatment effect documentation (e.g., slit lamp exam for cystinosis) and may be extended up to one year.

    • Initial approval periods often short (e.g., 3 months) to confirm benefit; renewals require objective clinical exam notes.
    • Prescriber specialty must be documented on the PA.
    Documentation Required

    Therapeutic Response Documentation for Continuation

    Therapeutic response documentation for continuation: For drugs with initial short approvals (e.g., DALFAMPRIDINE ER, Gattex, Signifor), provide objective evidence of clinical improvement at reauthorization (e.g., improved ambulation, reduced PN volume, decreased urinary cortisol). Without documented benefit, continuation may be denied.

    • Specify the outcome measures used to assess benefit and include before/after data when available.
    • Annual reauthorization often requires continued evidence of response.
    Documentation Required

    Clinical Benefit Documentation for Non‑Preferred Use

    Clinical benefit documentation for non‑preferred use: When a product is reserved for use only after failure of preferred products, include documentation from clinical notes or literature demonstrating benefit for the patient relative to preferred alternatives.

    • Attach peer‑reviewed literature or specialty society guidance when requested by the PA criteria.
    • Explain why preferred alternatives are clinically inappropriate or ineffective for this patient.
    Denial Risk

    Opioid Management Attestation

    Opioid management attestation: For long‑acting opioid PAs include a signed attestation that the prescriber is managing opioid therapy per guidelines, including screening, monitoring, and documentation of risk mitigation (PDMP checks, UDT, treatment agreements).

    • Attach the signed attestation and outline monitoring plan.
    • Include documentation of prior short‑acting opioid trial when required.
    Documentation Required

    Gattex Documentation

    Gattex documentation: Gattex (teduglutide) is reserved for adult patients with short bowel syndrome dependent on parenteral nutrition (e.g., ≥4L daily) for at least one year; initial approvals are for three months. Reauthorizations require documented reduction in parenteral nutrition volume and may be extended up to one year.

    • Provide baseline PN volume and duration of dependence (≥1 year).
    • For reauthorization, document reduction in PN volume and clinical status.
    Denial Risk

    Opioid Documentation

    Opioid documentation: For long‑acting opioids and products with opioid risk edits, include prior short‑acting opioid use documentation (minimum 30 days), provider attestation of guideline‑based management, quantity justification, and monitoring plan to meet PA criteria.

    • Provide pharmacy fill history or EHR medication list showing prior short‑acting opioid use and dates.
    • Describe opioid risk mitigation strategies in the patient chart.
    Documentation Required

    Supporting Literature

    Supporting literature: When a reserved product requires literature support demonstrating superiority or benefit over preferred products, include pertinent citations and a brief summary of how the evidence applies to the member’s case.

    • Include PDFs or links to key studies and an explanation of patient‑level applicability.
    • If literature is not definitive, provide detailed clinical rationale for exception.
    Documentation Required

    Trial and Documentation Requirements

    Trial and documentation requirements: For step therapy and reserved uses, clearly document all required trials (agent, dose, duration, outcome) and reasons for discontinuation. When trials are not feasible, provide clear medical rationale or allergy documentation.

    • Follow lookback windows and specified numbers of required failed agents (commonly two preferred alternatives).
    • If a required trial was not completed, provide clinical justification and supporting records.
    Documentation Required

    Nexletol / Nexlizet Documentation

    Nexletol / Nexlizet documentation: For initial approval include LDL ≥70 mg/dL despite high‑intensity statin (or documented intolerance) and prior trial of ezetimibe unless contraindicated. Reauthorizations require documentation of LDL reduction or provider attestation of benefit.

    • Include baseline and recent LDL values and statin/ezetimibe trial dates.
    • Provider attestation required at reauthorization confirming LDL improvement.
    Documentation Required

    PEGASYS Documentation

    PEGASYS documentation: For hepatitis B or C use, include specialist prescriber notes (GI/hepatology/infectious disease), HCV genotype and viral load when applicable, intolerance or adverse effects to prior therapy, and regimen details aligning with HealthPartners coverage criteria. Observe duration limits per genotype/indication.

    • Hepatitis B: limit coverage up to 48 weeks; HCV genotype 1: up to 48 weeks; genotypes 2/3: up to 24 weeks.
    • Attach genotype/viral load reports and prior Peg‑Intron intolerance documentation.
    Documentation Required

    Comparative Benefit Documentation

    Comparative benefit documentation: When coverage is sought for a non‑preferred product after failure of preferred agents, include comparative data or documented clinical reasons demonstrating why the non‑preferred product is expected to provide superior outcomes for this patient.

    • Summarize relevant comparative studies or clinical rationale in the PA submission.
    • If requested by PA criteria, attach literature PDFs.
    Documentation Required

    Pulmozyme Documentation

    Pulmozyme documentation: For cystic fibrosis therapies such as Pulmozyme and inhaled antibiotics, provide CF diagnosis confirmation, culture data where applicable, prescriber specialty (CF center), and evidence of clinical benefit for renewals.

    • Initial and renewal approvals may require CF center visit documentation within preceding 12 months.
    • Include pulmonary function tests or clinical notes showing benefit when requested.
    Documentation Required

    Clinical Response and Prior Therapy Documentation

    Clinical response and prior therapy documentation: Many specialty agents require demonstration of prior therapies tried and objective clinical response for continuation. For initial approvals, list prior treatments and reasons for failure; for continuations, provide measurable improvement and ongoing benefit.

    • Attach prior therapy lists with dates and reasons for discontinuation.
    • Provide objective response data (labs, imaging, functional status) for reauthorizations.
    Documentation Required

    Tobramycin Renewal Documentation

    Tobramycin renewal documentation: For inhaled tobramycin products used in CF, initial approvals are limited and renewals require documentation that the patient was seen within the past 12 months at a CF center and that therapy remains effective. Quantity limits (e.g., one 56‑count carton per 56 days) apply.

    • Include CF center visit in last 12 months and clinical effectiveness note.
    • Adhere to quantity limits per product entry.
    Documentation Required

    Follow Linked PA Criteria

    Follow linked PA criteria: Many PA requirements and specifics live in externally linked HealthPartners PDFs or web pages. Always follow those linked PA criteria when present; they often list required forms, labs, trial requirements, and specialty prescriber mandates.

    • If the formulary entry includes a URL, attach evidence requested by that page.
    • Use the external criteria to populate the PA submission fields accurately.
    Documentation Required

    Documentation of Prior Trials or Justification

    Documentation of prior trials or justification: Ensure prior therapy documentation lists drug name, dose, dates, adherence, and reason for discontinuation. If a prior trial was not possible, provide clinical justification (e.g., intolerance, contraindication) with supporting records.

    • Pharmacy fill history or EHR medication lists help verify trials and adherence.
    • Provider narrative should explain why step therapy could not be completed when applicable.
    Step Therapy

    Step Therapy Trials or Allergy Exception

    Step therapy trials or allergy exception: Step therapy rules often require trial and failure of a specified number of preferred agents (commonly one or two) before non‑preferred coverage. An allergy or medical contraindication to the preferred agent(s) can be an exception if well‑documented.

    • Document specific allergic reactions or contraindications with supporting clinical notes.
    • Specify which preferred agent(s) were tried and the clinical outcome.
    Step Therapy

    Step Therapy Summary for Multiple Drugs

    Step therapy summary for multiple drugs: Many entries use a consistent pattern — reserved for FDA‑approved indications, or after inadequate response to one or two preferred alternatives, or permitted for documented allergy to generics. Follow the pattern and include required documentation accordingly.

    • Check each product entry for the number of required failed agents and any specialty or lab requirements.
    • When in doubt, include more comprehensive prior therapy history to satisfy criteria.
    Step Therapy

    Step Therapy Trials Required

    Step therapy trials required: For products that require trials of preferred agents, include the required number of failed alternatives and supporting documentation. Some products also require documentation that preferred alternatives were used at adequate dose and duration.

    • List dose and duration for each prior trial to demonstrate adequacy.
    • Include reasons for failure (inefficacy, adverse effects) rather than simply stating 'failed'.
    Step Therapy

    Step Therapy / Reserved Use Patterns

    Step therapy / reserved use patterns: Typical patterns include: (1) reserved for documented allergy to equivalent generic; (2) reserved after failure of one preferred alternative; (3) reserved after failure of two preferred alternatives with literature support; (4) reserved for FDA‑approved indications only. Confirm which pattern applies to each product.

    • When literature support is requested, provide citations and patient‑level rationale.
    • Allergy exceptions require specific documentation of the allergic event.
    Step Therapy

    Step Therapy: Trials of Preferred Alternatives

    Step therapy: trials of preferred alternatives: Many drugs require trials of preferred alternatives before coverage of the non‑preferred product. Document trials clearly and include dates, doses, and outcomes to satisfy PA reviewers.

    • Preferred alternatives and required trial counts are specified in product entries; follow them.
    • If preferred alternatives were not tolerated, include clinical notes and adverse event descriptions.
    Step Therapy

    Step Therapy / Reserved Status

    Step therapy / reserved status: For drugs designated reserved, coverage is limited to the specific reserved status reason. Provide the exact supporting documentation required (e.g., allergy, contraindication, failure of preferred therapy, specialist prescribing) when requesting coverage.

    • Use the reserved reason verbatim in the PA request and attach corroborating records.
    • If the reserved reason is 'FDA‑approved indications only,' include diagnostic documentation matching the FDA indication.
    Step Therapy

    Step Therapy Rules Summary

    Step therapy rules summary: Step therapy requires prior use and failure of specified preferred therapies, with lookback periods and trial durations defined in many entries. Exceptions (allergy, intolerance, medical contraindication, specialist recommendation) must be supported with documentation.

    • Confirm lookback periods (commonly 12 months) and required number of failed agents in product entries.
    • Provide clear clinical justification for any requested exception.
    Step Therapy

    Step Therapy: Inadequate Response to Preferred Products

    Step therapy: inadequate response to preferred products: When a product is covered only after inadequate response to preferred options, include objective evidence of inadequate response (lab values, symptom measures, imaging, or clinical notes).

    • Objective measures strengthen PA approvals (e.g., symptom scores, lab trends).
    • Narrative alone is less persuasive — include data when possible.
    Step Therapy

    Step Therapy: Allergic Reaction Exemptions

    Step therapy: allergic reaction exemptions: Documented allergic reactions to preferred or generic alternatives can exempt the member from step requirements if clearly evidenced in the medical record.

    • Include allergy testing results or contemporaneous provider notes describing the allergic reaction.
    • State which agent caused the reaction and the nature/severity of the reaction.
    Step Therapy

    Step Therapy Requirements Noted

    Step therapy requirements noted: Many formulary entries include concise step therapy statements (e.g., one or two failed preferred agents, specialist prescribing, or allergy exceptions). Carefully follow those noted requirements and prepare documentation accordingly.

    • When product entries reference external PDFs for full criteria, follow and attach the external guidance.
    • A checklist approach (diagnosis, prior trials, labs, prescriber specialty) helps ensure complete submissions.
    Note

    Background

    Background: PA and step therapy are utilization management tools used by HealthPartners to ensure appropriate, safe, and cost‑effective use of medications. PA verifies that a requested medicine meets the plan’s coverage criteria; step therapy directs use of preferred, lower‑cost alternatives first unless there is clinical justification for exception.

    Key Coding and Thresholds

    LDL threshold for Nexletol/Nexlizet
    LDL threshold>= 70 mg/dL
    Applicable productsNexletol, Nexlizet
    Context for requirementRequired after inadequate response to high‑intensity statin therapy (or statin contraindication) and inadequate response to ezetimibe
    Authorization durationApprovals given for one year; reauthorizations require documentation of LDL reduction per provider attestation
    Short-acting opioid trial duration — minimum of 30 days of continuous use
    Minimum trial durationMinimum of 30 days of continuous use of a short‑acting opioid
    ApplicabilityRequired prior to initiating long‑acting opioid therapy (provider attestation required)
    Attestation requirementProvider must attest that opioid therapy is managed per standard opioid prescribing guidelines
    Related denial riskLack of attestation or trial documentation may trigger denial
    BACKGROUND
    PurposeExplains Prior Authorization (PA) and Step Therapy (ST) as utilization management tools to ensure drugs meet payer coverage criteria
    PA definitionRequirement that certain medicines meet HealthPartners prior authorization criteria to be covered by pharmacy benefits
    ST definitionPolicy where a member must try one or more other medicines first; coverage is provided if required alternatives have been tried or approval obtained

    Initial Therapy and Authorization Rules

    Continuation / Reauthorization Requirements